Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16429271rdf:typepubmed:Citationlld:pubmed
pubmed-article:16429271lifeskim:mentionsumls-concept:C0040300lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0035804lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0026336lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0023903lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0009924lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0024485lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0850292lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:16429271lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:16429271pubmed:issue5lld:pubmed
pubmed-article:16429271pubmed:dateCreated2006-4-11lld:pubmed
pubmed-article:16429271pubmed:abstractTextWe exploited a necrosis-avid contrast agent ECIV-7 for magnetic resonance imaging (MRI) in rodent liver tumors after radiofrequency ablation (RFA). Rats bearing liver rhabdomyosarcoma (R1) were randomly allocated to three groups: group I, complete RFA, group II, incomplete RFA, and group III, sham ablation. Within 24 h after RFA, T1-weighted (T1-w) MRI was performed before and after injection of ECIV-7 at 0.05 mmol/kg and followed up from 6-24 h. Signal intensities (SIs) were measured with relative enhancement (RE) and contrast ratio (CR) calculated. The MRI findings were verified histomorphologically. On plain T1-w MRI the contrasts between normal liver, RFA lesion, residual and/or intact tumor were vague. Early after administration of ECIV-7, the liver SI was strongly enhanced (RE=40-50%), leaving the RFA lesion as a hypointense region in groups I and II. At delayed phase, two striking peri-ablational enhancement patterns appeared (RE=90% and CR=1.89%), i.e., "O" type of hyperintense rim in group I and "C" type of incomplete rim in group II. These MRI manifestations could be proven histologically. In this study, tissue components after RFA could be characterized with discernable contrasts by necrosis-avid contrast agent (NACA)-enhanced MRI, especially at delayed phase. This approach may prove useful for defining the ablated area and identifying residual tumor after RFA.lld:pubmed
pubmed-article:16429271pubmed:languageenglld:pubmed
pubmed-article:16429271pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16429271pubmed:citationSubsetIMlld:pubmed
pubmed-article:16429271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16429271pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16429271pubmed:statusMEDLINElld:pubmed
pubmed-article:16429271pubmed:monthMaylld:pubmed
pubmed-article:16429271pubmed:issn0938-7994lld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:YuZ PZPlld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:LaxYYlld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:VerbruggenAlf...lld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:NiYichengYlld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:MarchalGuyGlld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:LanduytWillyWlld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:MulierStefaan...lld:pubmed
pubmed-article:16429271pubmed:authorpubmed-author:SunXiheXlld:pubmed
pubmed-article:16429271pubmed:issnTypePrintlld:pubmed
pubmed-article:16429271pubmed:volume16lld:pubmed
pubmed-article:16429271pubmed:ownerNLMlld:pubmed
pubmed-article:16429271pubmed:authorsCompleteYlld:pubmed
pubmed-article:16429271pubmed:pagination1031-40lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:meshHeadingpubmed-meshheading:16429271...lld:pubmed
pubmed-article:16429271pubmed:year2006lld:pubmed
pubmed-article:16429271pubmed:articleTitleMagnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent.lld:pubmed
pubmed-article:16429271pubmed:affiliationDepartment of Radiology, University Hospitals, Catholic University of Leuven, Herestraat 49, 3000 Leuven, Belgium. Yicheng.Ni@med.kuleuven.ac.belld:pubmed
pubmed-article:16429271pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16429271pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16429271pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16429271lld:pubmed